LOGIN  |  REGISTER

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 584.05
-0.98 -0.17
816,724
381.72M
US$ 222.940B
US$ 262.78
1.38 0.53
1.94M
740.69M
US$ 194.640B
US$ 127.37
1.77 1.41
2.27M
397.68M
US$ 50.650B
US$ 150.66
0.11 0.07
738,800
293.06M
US$ 44.150B
US$ 516.50
0.40 0.08
264,934
82.59M
US$ 42.660B
US$ 229.60
2.51 1.11
710,126
182.20M
US$ 41.830B
US$ 1.00
0.23 0.02
100,885
21.36M
US$ 31.600B
US$ 320.72
0.72 0.22
573,662
82.68M
US$ 26.520B
US$ 336.46
-0.33 -0.10
441,918
59.32M
US$ 19.960B
US$ 106.48
0.63 0.60
1.09M
159.30M
US$ 16.960B
US$ 199.65
2.56 1.30
711,796
84.29M
US$ 16.830B
US$ 141.28
1.24 0.89
597,961
111.09M
US$ 15.690B
US$ 113.27
1.38 1.23
627,358
123.52M
US$ 13.990B
US$ 109.51
2.00 1.86
652,260
122.80M
US$ 13.450B
US$ 390.55
-0.03 -0.01
104,375
30.98M
US$ 12.100B
US$ 217.21
-0.34 -0.16
301,855
51.51M
US$ 11.190B
US$ 43.73
0.56 1.30
602,713
221.85M
US$ 9.700B
US$ 49.84
-4.24 -7.84
6.00M
184.53M
US$ 9.200B
US$ 78.22
-0.78 -0.99
838,853
69.31M
US$ 5.420B
US$ 58.54
0.89 1.54
384,289
73.88M
US$ 4.320B
US$ 11.20
0.01 0.09
899,622
283.07M
US$ 3.170B
US$ 25.52
3.01 13.37
5.96M
122.37M
US$ 3.120B
US$ 23.97
0.04 0.17
412,266
124.34M
US$ 2.980B
US$ 13.26
-0.04 -0.30
1.26M
216.61M
US$ 2.870B
US$ 42.40
0.55 1.31
785,195
66.97M
US$ 2.840B
US$ 42.23
0.87 2.10
685,529
58.23M
US$ 2.460B
US$ 23.16
-0.11 -0.47
337,815
90.51M
US$ 2.100B
US$ 14.24
0.35 2.52
495,179
127.71M
US$ 1.820B
US$ 2.54
-0.07 -2.68
1.82M
378.86M
US$ 962.300M
US$ 1.36
0.08 6.25
2.25M
696.99M
US$ 947.910M
US$ 15.94
0.11 0.69
583,873
52.08M
US$ 830.160M
US$ 30.34
0.09 0.30
35,498
23.88M
US$ 724.520M
US$ 24.37
0.63 2.65
123,033
27.61M
US$ 672.860M
US$ 21.39
0.25 1.18
100,385
29.92M
US$ 639.990M
US$ 1.87
-0.07 -3.61
7.97M
272.36M
US$ 509.310M
US$ 8.65
0.39 4.72
93,325
31.69M
US$ 274.120M
US$ 1.62
-0.04 -2.41
560,726
121.88M
US$ 197.450M
US$ 1.45
0.04 2.84
45,415
114.69M
US$ 166.300M
US$ 0.51
0.0036 0.71
6.89M
315.44M
US$ 161.850M
C$ 0.49
-0.005 -1.02
15,186
278.58M
C$ 135.110M
US$ 4.03
0.00 0.00
0
31.62M
US$ 127.270M
US$ 7.55
-0.02 -0.26
531
10.26M
US$ 77.460M
US$ 2.73
-0.04 -1.44
21,377
27.29M
US$ 74.500M
US$ 2.72
0.02 0.74
314,336
26.33M
US$ 71.620M
US$ 1.07
0.04 3.88
646,474
66.86M
US$ 71.540M
US$ 4.95
-0.21 -4.07
150,219
13.54M
US$ 67.020M
US$ 2.18
-0.12 -5.22
138,500
30.00M
US$ 65.400M
US$ 0.73
-0.01 -2.01
127,219
82.82M
US$ 60.260M
US$ 1.07
0.02 1.90
26,821
51.23M
US$ 54.820M
US$ 1.76
0.16 10.00
124,217
29.67M
US$ 52.220M
US$ 2.00
0.02 1.01
169,315
25.79M
US$ 51.580M
C$ 0.38
0.00 0.00
0
109.52M
C$ 41.620M
US$ 1.06
-0.02 -1.85
76,031
31.28M
US$ 33.160M
US$ 1.86
-0.14 -7.00
37,624
17.37M
US$ 32.310M
US$ 2.67
0.21 8.54
105,027
11.51M
US$ 30.730M
US$ 1.38
0.11 8.24
295,669
22.05M
US$ 30.430M
US$ 2.29
-0.04 -1.72
64,205
12.34M
US$ 28.260M
C$ 0.23
0.00 0.00
12,000
90.89M
C$ 20.450M
US$ 1.69
0.06 3.68
5,880
9.47M
US$ 16.000M
C$ 0.16
0.00 0.00
38,700
99.64M
C$ 15.440M
US$ 2.57
-0.12 -4.46
1,982
5.81M
US$ 14.930M
US$ 0.39
0.02 6.53
665,328
34.96M
US$ 13.630M
US$ 2.27
0.00 0.00
9,699
5.85M
US$ 13.280M
C$ 0.18
-0.01 -5.26
43,500
71.31M
C$ 12.840M
US$ 0.57
0.0089 1.58
69,440
21.89M
US$ 12.510M
US$ 1.00
0.0064 0.65
66,098
11.43M
US$ 11.400M
US$ 0.37
-0.0061 -1.60
51,373
27.87M
US$ 10.420M
US$ 2.14
-0.04 -1.83
21,505
4.41M
US$ 9.440M
US$ 5.87
-0.21 -3.45
1,610
1.47M
US$ 8.630M
C$ 0.12
0.00 0.00
500
55.00M
C$ 6.600M
US$ 0.02
0.00 0.00
0
286.49M
US$ 5.590M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
94.47M
C$ 4.720M
US$ 3.30
0.03 0.92
53,709
1.26M
US$ 4.160M
US$ 0.28
0.0011 0.39
51,100
11.04M
US$ 3.120M
US$ 0.31
0.02 7.66
2.29M
9.98M
US$ 3.070M
US$ 0.02
0.00 0.00
0
161.02M
US$ 2.580M
US$ 1.99
-0.04 -1.97
81,083
984,728
US$ 1.960M
US$ 0.14
-0.04 -20.46
122,952
5.21M
US$ 719K
US$ 5.76
-0.08 -1.37
13,939
-
US$ -

Latest News From Diagnostics & Research Stocks


Fulgent Genetics Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

EL MONTE, Calif. / May 24, 2024 / Business Wire / Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois. Details of the... Read more


Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

Data to be presented expands the body of evidence around the predictive and prognostic value of the Oncotype DX® test in all racial and ethnic groups New data showcase Exact Sciences’ commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients MADISON, Wis. / May 24, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10... Read more


Guardant Health: FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood test that meets performance requirements for Medicare coverage1 PALO ALTO, Calif. / May 23, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,... Read more


Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad C... Read more


Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

AUSTIN, Texas / May 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera’s management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly... Read more


23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be... Read more


Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast. A... Read more


Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. / May 23, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads... Read more


Agilent Technologies Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse... Read more


Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

AUSTIN, Texas / May 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. The presentations feature data across a variety of indications, including breast cancer, colorectal cancer (CRC), lung cancer, melanoma, esophageal cancer,... Read more


Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025 Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further improvements expected through 2024 and into... Read more


Agilent Technologies at ASMS 2024: Driving Scientific Breakthroughs with Unparalleled Mass Spec Solutions

SANTA CLARA, Calif. / May 22, 2024 / Business Wire / Agilent Technologies Inc., (NYSE: A) will showcase its latest mass spectrometry innovations at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, scheduled for June 2 - 6, 2024, in Anaheim, California. A global leader in analytical instruments, Agilent continues to drive performance and accessibility in mass spectrometry. “Agilent will make a significant impact at this year’s ASMS Conference, unveiling... Read more


Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption of guideline-recommended genomic profiling to inform optimal therapy selection for patients with advanced cancer PALO ALTO, Calif. / May 21, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its... Read more


Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company’s lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease... Read more


Bionano Genomics Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer’s disease Taken... Read more


Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema LOUISVILLE, Colo. / May 21, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society (ATS) International Conference in San Diego, California. The presentation, titled "Performance comparison of a blood-based integrated... Read more


HeartBeam’s Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company’s AI Program Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter SANTA CLARA, Calif. / May 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study data demonstrating that HeartBeam... Read more


Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company’s mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer... Read more


ENDRA Life Sciences Provides Update Following In-person Meeting with FDA

Increases clarity for ENDRA on regulatory path forward for TAEUS ANN ARBOR, Mich. / May 20, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing. Prior... Read more


Anna Richo joins Illumina's Board of Directors

Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience to Illumina's Board SAN DIEGO, May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Ms. Richo currently serves as Corporate Senior Vice President, Strategic Advisor to the General Counsel... Read more


StageZero Life Sciences Announces Q1 2024 Financial Results and Operational Update

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its first quarter financial results for the three... Read more


T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants... Read more


Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results Two-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function BRISBANE, Calif. / May 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the... Read more


New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation... Read more


Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this collaboration, Trinity Biotech will... Read more


Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week

PALO ALTO, Calif. / May 16, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening. “One in three eligible American adults have not been screened for CRC, in part because the currently available methods are... Read more


Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21

AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner’s Healthcare Showcase taking place virtually on Tuesday, May 21, 2024. Presentation Details: Date: Tuesday, May 21, 2... Read more


Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors

SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting... Read more


Mdxhealth to Present at Upcoming Investor Conferences

IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024. William Blair 44th Annual Growth Stock ConferencePresentation: Wednesday, June 5, at 5:00pm ETWebcast: https://wsw.com/webcast/blair97/mdxh/1942906 Jefferies Global Healthcare Conferenc... Read more


Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine... Read more


bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast KOL referrals and word-of-mouth expanding adoption of CyPath® Lung outside of the beta market launch in Texas SAN ANTONIO / May 15, 2024 / Business Wire / bioAffinity Technologies, Inc.... Read more


Telo Genomics and Emery Pharma Announce Collaboration

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ("Emery"). Emery is a full-service contract research organization (CRO) offering biologic drug development support and... Read more


Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy

Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C., May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of... Read more


Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

FRIENDSWOOD, Texas / May 15, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’... Read more


T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase... Read more


Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update

Second quarter fiscal 2024 revenue down 21.5% to $119.0 million Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million Agreement in principle reached with the U.S. Department of Justice on related matter Site optimization projects near completion Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical... Read more


DarioHealth Reports First Quarter 2024 Financial and Operating Results

First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues. Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from $1.12 million in the fourth quarter... Read more


Aspira Women’s Health Reports First Quarter 2024 Financial Results

Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported... Read more


Centogene Reports Full Year 2023 Financial Results and Recent Business Highlights

Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF Positioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15% Ongoing strategic alternatives process focused... Read more


QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support

Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of hereditary and somatic diseases, has received the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation (EU) 2017/746... Read more


Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine TAMPA, Fla. & LOS ANGELES / May 14, 2024 / Business Wire / Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic... Read more


IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day

WESTBROOK, Maine / May 14, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT). A... Read more


Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024. The poster, titled, “Combination therapy of the FXR agonist FXR314... Read more


Centogene and Evotec Discover Promising New Molecule to Treat Gaucher Disease

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential... Read more


Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations...

In collaboration with leading GI experts, Castle has also planned several educational sessions at DDW 2024, including a product theater and two American Society for Gastrointestinal Endoscopy (ASGE) theater talks FRIENDSWOOD, Texas / May 14, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share three abstracts supporting the ability of its TissueCypher® test to predict... Read more


DermTech Reports First-Quarter 2024 Financial Results

Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year Test revenue increased 7 percent versus the first quarter of 2023 SAN DIEGO / May 14, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume... Read more


Psychemedics Reports First Quarter 2024 Financial Results

DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4... Read more


ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / May 14, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update. Highlights from the first quarter of 2024 and recent weeks include: Installed the first TAEUS system in the UK at King’s College Hospital for clinical... Read more


Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales

DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million. The Company has successfully scaled up production to meet the increased demand... Read more


Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA 's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade (GMP) CAR T-cell therapies has been accepted for presentation at the prestigious... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB